NASDAQ:BTTX Better Therapeutics (BTTX) Stock Price, News & Analysis → How to Make 100X on the AI Boom (From InvestorPlace) (Ad) Free BTTX Stock Alerts $0.01 0.00 (0.00%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$0.0085▼$0.012250-Day Range$0.01▼$0.2252-Week Range$0.01▼$1.35Volume37,935 shsAverage Volume282,524 shsMarket Capitalization$607,294.80P/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Better Therapeutics alerts: Email Address Ad InvestorPlaceCrypto Millionaire Says: “Buy This $11 AI Coin.”Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos.Find out more about this $11 AI Coin right now About Better Therapeutics Stock (NASDAQ:BTTX)Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.Read More BTTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTTX Stock News HeadlinesMay 6, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Springworks Therapeutics (SWTX) and Becton Dickinson (BDX)May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Context Therapeutics Amid Promising CTIM-76 Developments and Competitive EdgeApril 26, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY)April 10, 2024 | msn.comPrecision Combination Therapy Better Controls High-Risk Subtypes of B-ALL in Mouse ModelsMarch 16, 2024 | uk.investing.comBetter Therapeutics plans employee layoffs, strategic reviewMarch 14, 2024 | markets.businessinsider.comDow Dips Over 100 Points; Dick's Sporting Goods Earnings Top ViewsMarch 14, 2024 | businesswire.comBetter Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from NasdaqMarch 5, 2024 | businesswire.comBetter Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health CentersMarch 4, 2024 | finance.yahoo.comBetter Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)February 22, 2024 | finance.yahoo.comCAH Feb 2024 107.000 putFebruary 20, 2024 | benzinga.comWhy Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionFebruary 20, 2024 | marketwatch.comBetter Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy PlatformFebruary 20, 2024 | businesswire.comBetter Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver DiseaseFebruary 6, 2024 | markets.businessinsider.comBuy Rating on Astria Therapeutics Supported by STAR-0215’s Promising Market Potential and Favorable Trial ResultsFebruary 6, 2024 | marketwatch.comBetter Therapeutics Enters Rebate Agreement with Pharmacy Benefit ManagerFebruary 6, 2024 | finance.yahoo.comBetter Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes TreatmentJanuary 18, 2024 | finance.yahoo.comDavid Perry Bought 8.6% More Shares In Better TherapeuticsJanuary 17, 2024 | finance.yahoo.comBetter Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care AloneJanuary 16, 2024 | tmcnet.comBiora Therapeutics Provides Outlook for 2024January 3, 2024 | finance.yahoo.comBetter Therapeutics Insiders Added US$6.57m Of Stock To Their HoldingsJanuary 2, 2024 | msn.comBetter Therapeutics applies for FDA breakthrough designation for NASH deviceJanuary 2, 2024 | finance.yahoo.comBetter Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver DiseaseDecember 13, 2023 | msn.comBetter Therapeutics files to sell 20M shares of common stock for holdersDecember 12, 2023 | msn.comBetter Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?November 29, 2023 | msn.comBetter Therapeutics amends debt facility, implements cost-saving measuresSee More Headlines Receive BTTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:BTTX CUSIPN/A CIK1832415 Webmcacquisition.com Phone415-887-2311FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+49,161.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,760,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-217.46% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio0.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-0.30Miscellaneous Outstanding Shares49,860,000Free Float24,233,000Market Cap$607,294.80 OptionableOptionable Beta2.07 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. David P. Perry M.B.A. (Age 56)Co-Founder & Executive Chairman Comp: $260kMr. Frank L. Karbe (Age 56)CEO, Interim CFO, President & Director Comp: $533.37kDr. Mark A. Berman M.D. (Age 48)Chief Medical Officer Comp: $573.75kMs. Kristin Wynholds (Age 51)Chief Product Officer Comp: $519.07kMr. Andres CamachoSenior VP of Technology & Head of EngineeringMs. Angela WillisSenior Vice President of Market AccessMs. Jessica MengChief Commercial OfficerLeslie MillerControllerMore ExecutivesKey CompetitorsAptevo TherapeuticsNASDAQ:APVOAditxtNASDAQ:ADTXChina SXT PharmaceuticalsNASDAQ:SXTCInvitaeNYSE:NVTAMotus GINASDAQ:MOTSView All CompetitorsInsidersDavid P PerryBought 1,233,045 shares on 7/27/2023Total: $900,122.85 ($0.73/share)Andrew J ArmaninoBought 274,010 shares on 7/27/2023Total: $200,027.30 ($0.73/share)Frank KarbeBought 137,005 shares on 7/27/2023Total: $100,013.65 ($0.73/share)Mark A BermanBought 54,802 shares on 7/27/2023Total: $40,005.46 ($0.73/share)Elder GrangerBought 600 shares on 5/16/2023Total: $522.00 ($0.87/share)View All Insider Transactions BTTX Stock Analysis - Frequently Asked Questions Should I buy or sell Better Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTTX shares. View BTTX analyst ratings or view top-rated stocks. What is Better Therapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 12-month price targets for Better Therapeutics' stock. Their BTTX share price targets range from $3.00 to $9.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 49,161.1% from the stock's current price. View analysts price targets for BTTX or view top-rated stocks among Wall Street analysts. How have BTTX shares performed in 2024? Better Therapeutics' stock was trading at $0.1950 at the beginning of the year. Since then, BTTX shares have decreased by 93.8% and is now trading at $0.0122. View the best growth stocks for 2024 here. How do I buy shares of Better Therapeutics? Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTTX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportGuard Against the Coming Financial UpheavalPorter & CompanyDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThis 1 Biotech Stock has been shocking the marketsHuge AlertsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Better Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
